# Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

> **NCT00876031** · PHASE3 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 195 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** trofosfamide, idarubicin, etoposide

## Key facts

- **NCT ID:** NCT00876031
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876031, "Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00876031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*